Industrial Policy & Trade Monitor· 2663 actions· ✨ 89 recent

On 8 May 2026 China's National Health Commission released a public consultation draft proposing material amendments to the 2023 Implementation Rules for the Administrative Regulations on Human Genetic Resources, with a comment deadline of 7 June 2026. The draft narrows the statutory "foreign party" definition to a bright-line 50% equity/voting threshold (excluding VIE-structured entities), restricts "HGR Information" strictly to nucleic-acid sequence data (excluding clinical, imaging, and metabolic data), removes the separate Article 37 security-review requirement for sensitive HGR datasets, and introduces a same-day or next-working-day fast-track confirmation for international clinical trials not involving HGR information export.

The Office of the United States Trade Representative released the 2026 Special 301 Report on 30 April 2026, designating Vietnam as a Priority Foreign Country (PFC) — the most severe category under Section 182 of the Trade Act of 1974 (19 U.S.C. § 2242). This is the first PFC designation since Ukraine held the status from 2013 through 2015, a gap of approximately 11 years. The PFC designation triggers a statutory 30-day window (expiring ~30 May 2026) within which USTR must decide whether to initiate a Section 301 investigation under 19 U.S.C. § 2412(b)(2)(A), which could lead to tariffs, withdrawal of trade benefits, or other Section 301 enforcement remedies against Vietnam. Separately, the EU was added to the Watch List for the first time, citing AI training-data, geographical-indications, and customs-enforcement concerns.

On 26 April 2026, the UAE Cabinet, chaired by Vice President and Prime Minister Sheikh Mohammed bin Rashid Al Maktoum, approved a four-part industrial-resilience package: (i) a National Industrial Resilience Fund with AED 1 billion (~USD 272m) capital managed by Emirates Development Bank over five years covering food industries, manufacturing, primary metals, mechanical/electrical/chemical industries, pharmaceuticals and medical supplies, advanced technology, and construction — designed to localise over 5,000 critical products and link confirmed procurement demand with targeted financing for local manufacturers; (ii) structural overhaul of the National In-Country Value (ICV) Programme, transitioning it from incentive-based to MANDATORY across federal entities and companies in which the government holds 25% or more; (iii) a National Product Retail Presence Policy strengthening visibility of UAE-manufactured goods in retail and digital channels (Phase 1: bottled water, dairy, eggs, poultry, bread, flour, vegetable oils, seasonal vegetables); and (iv) a National Industrial Data Committee chaired by Hasan Jassim Al Nowais (Undersecretary, MoIAT), with AI-driven forecasting and risk management integrated into industrial-resilience monitoring.

On 2 April 2026 President Trump issued a Presidential Proclamation under Section 232 of the Trade Expansion Act of 1962 ("Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States") imposing a 100% ad valorem tariff on imports of patented pharmaceutical products listed in the FDA Orange Book and Purple Book, together with the active pharmaceutical ingredients (APIs) and key starting materials used to make them. The base rate takes effect at 12:01 a.m. EDT on 31 July 2026 for the 17 manufacturers identified in Annex III, and on 29 September 2026 for all other companies. The proclamation adopts findings of the Section 232 investigation initiated by the Department of Commerce on 14 April 2025 into pharmaceuticals and APIs as a national- security supply-chain risk. The instrument is structured around a multi-tier rate ladder rather than a flat tariff: concessionary 15% rates for EU/Japan/South Korea/Switzerland/Liechtenstein under reciprocal-deal tracks, 10% for the UK with a pathway to 0% under the pending UK pharmaceutical agreement, a "+20%" surcharge for companies operating under a Commerce-approved onshoring plan (until 2 April 2030), and a 0% pathway for companies that combine an approved onshoring plan with an MFN-pricing agreement with HHS (until 20 January 2029). Generics, biosimilars and their ingredients, orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, and cell/gene therapies are carved out.

Premier Li Qiang signed State Council Order No. 834 on 31 March 2026 promulgating the "Provisions on Industrial Chain and Supply Chain Security" (18 articles), adopted at the State Council executive meeting on 13 March 2026 and effective on the date of publication. The Provisions are the first dedicated PRC administrative regulation on industrial- and supply-chain security and consolidate authorities drawn from the National Security Law, Foreign Relations Law, Anti-Foreign Sanctions Law, and Foreign Trade Law into a horizontal defensive framework. They establish a cross-agency coordination mechanism spanning roughly 15 central departments (industrial, security, cyberspace, customs and financial regulators) plus provincial governments; create a security-investigation system; and vest broad countermeasure authority over both foreign states (Article 14 — import/export prohibitions and special levies) and foreign organisations and individuals (Article 15 — import/export bans, China-investment bars, transaction prohibitions, entry bars and revocation of work or residence permits, with extension to effectively-controlled subsidiaries). The Provisions also impose compliance, information-sharing, strategic-reserve and emergency-response obligations on PRC organisations and individuals, and authorise requisition, mandated production and directed transportation in the event of supply-chain disruption.

On 1 May 2026 the trade pillar of the EU-Mercosur Partnership Agreement (the "Interim Trade Agreement", iTA) entered provisional application between the European Union and the four Mercosur states — Argentina, Brazil, Paraguay and Uruguay — following its publication in the EU Official Journal on 27 February 2026 alongside the broader EU-Mercosur Partnership Agreement (EMPA). The iTA covers goods (eliminating duties on more than 90% of bilateral trade over a transition period including immediate cuts on cars, pharmaceuticals, wine and olive oil), services, government procurement at federal and state level, intellectual property (344 EU geographical indications protected), SPS/TBT disciplines, and a sustainability chapter. Mercosur receives tariff-rate quotas on agri-food exports (beef, poultry, sugar, ethanol, honey). Provisional application proceeds pending full ratification of EMPA by the Council, European Parliament and all EU national parliaments and a pending CJEU opinion; only the trade pillar applies provisionally.

President Trump signed a Presidential Proclamation on 20 February 2026 invoking Section 122 of the Trade Act of 1974 (19 U.S.C. § 2132) to impose a temporary 10% ad-valorem import surcharge on articles imported into the United States, effective 12:01 a.m. EST on 24 February 2026. The proclamation was issued within hours of the US Supreme Court's 20 February 2026 ruling in Learning Resources, Inc. v. Trump, which held that the International Emergency Economic Powers Act (IEEPA) does not authorize the president to set tariffs and vacated the IEEPA-based reciprocal-tariff regime previously in effect. The Section 122 surcharge is statutorily limited to 150 days (terminates 24 July 2026 absent Congressional extension) and the statute caps any such surcharge at 15% ad valorem. Goods qualifying as USMCA originating from Canada or Mexico are exempt; CAFTA-DR textile/apparel articles meeting specified rules of origin are exempt; and a substantial product-exception list excludes critical minerals, energy products, certain pharmaceuticals, electronics, vehicles, aerospace products, specified agricultural goods, and goods already subject to Section 232 duties (the Section 122 duty does not stack on Section 232).

Brazil's Foreign Trade Chamber Executive Committee (GECEX/CAMEX) adopted Resolução GECEX nº 855 on 13 February 2026, imposing a five-year definitive antidumping duty on hypodermic needles (agulhas hipodérmicas) originating from China, classified under NCM tariff code 9018.32.19 (other tubular metal needles). The duty is collected as a specific tariff fixed in US dollars per thousand units, with rates ranging from USD 0.23 to USD 25.57/thousand units depending on the Chinese producer/exporter. The measure was published in the Diário Oficial da União (DOU Edição 32) on 18 February 2026, enters into force from publication, and marks the first medical-device trade-remedy action on the IPTM register. Scope exclusions cover insulin needles, biopsy needles, animal insemination needles, anesthesia needles, bulk non-sterile needles, and non-hypodermic needles.

On 12 February 2026, Ambassador Jamieson Greer of the Office of the United States Trade Representative oversaw the signing of the US-Taiwan Agreement on Reciprocal Trade (ART) in Washington, DC. The instrument was signed under the auspices of the American Institute in Taiwan (AIT) and the Taipei Economic and Cultural Representative Office in the United States (TECRO). Headline terms: (i) US IEEPA reciprocal-tariff rate on Taiwan reduced from 20% to 15% and Section 232 auto-parts/timber/lumber rate cut from 25% to 15%; (ii) Taiwan eliminates or reduces 99% of its tariff barriers on US goods, most immediately and the remainder phased over three years; (iii) Taiwan side commits ~USD 85bn in directed purchases through 2029 (USD 44.4bn LNG/crude, USD 15.2bn civil aircraft and engines, USD 25.2bn power equipment); (iv) sectoral chapters covering tariffs, non-tariff barriers, digital trade, economic security, and high-tech supply-chain resilience. Operationally linked to the 15 January 2026 AIT-TECRO Memorandum of Understanding on investment, under which Taiwan pledges USD 250bn in direct Taiwanese-enterprise investment in the US plus USD 250bn in Taiwan-government credit guarantees (USD 500bn total) to fund US-side industrial parks/clusters in advanced semiconductors, energy, and AI manufacturing. Entry into force is conditional on Taiwan's Legislative Yuan completing its review.

On 9 February 2026 USTR Ambassador Jamieson Greer and Bangladesh Adviser Sheikh Bashir Uddin signed the Agreement on Reciprocal Trade (ART) between the United States and Bangladesh in Washington DC — USTR's first ART signing in South Asia, preceding the US-India interim-trade-framework finalisation by three days. The deal locks the US reciprocal tariff on Bangladesh-originating goods at 19% (down from 35% under the April 2025 IEEPA regime) and establishes a zero-percent mechanism for products on the Annex III aligned- partner list (EO 14346, 5 September 2025). Bangladesh commits to significant preferential market access for US industrial and agricultural goods — including chemicals, machinery, motor vehicles, medical devices, ICT equipment, energy products, soy, dairy, beef, poultry, tree nuts, and fruit — and to eliminating specified non- tariff barriers including acceptance of US Federal motor-vehicle safety and emissions standards, FDA certificates, and prior marketing authorisations for medical devices and pharmaceuticals.

Brazil's federal innovation-financing agency FINEP (Financiadora de Estudos e Projetos), under the MCTI/FNDCT umbrella, published a BRL 300 million (~USD 51.7 million) public call — "Finep Mais Inovação Brasil – Rodada 2 – Saúde" — offering non-repayable economic-subsidy grants for private-sector R&D of innovative products or processes for Brazil's health-industrial complex (pharmaceuticals, health-sector chemical inputs). A minimum BRL 90 million is reserved for projects based in the North, Northeast or Center-West regions. Proposal submission opened 2026-02-06 and runs through 2026-09-18.

On 6 February 2026 Presidents Trump and Modi announced a framework for an Interim Trade Agreement that resets the bilateral tariff posture installed in 2025. Two operative instruments: (i) an executive order signed 6 February eliminating, effective 7 February 2026, the additional 25% IEEPA "Russian-oil" duty on Indian imports imposed by EO 14329 (27 August 2025), conditional on India's commitment to cease buying Russian crude and to expand defence cooperation; and (ii) reduction of the EO 14257 reciprocal-tariff rate on India from 25% to 18% on listed product categories (textiles and apparel, leather and footwear, plastics and rubber, organic chemicals, home décor, artisanal products, certain machinery), to take effect on finalisation of the Interim Agreement. India commits to eliminate or reduce tariffs on all US industrial goods and a wide range of agricultural products (DDGs, red sorghum, tree nuts, fresh and processed fruit, soybean oil, wine, spirits) and to purchase >USD 500bn of US energy, ICT, coal, aircraft and aircraft parts, and precious-metals products over five years. The framework also commits the parties to negotiating "robust, ambitious, and mutually beneficial digital trade rules" and to addressing non-tariff barriers in medical devices, ICT import licensing, and food/agricultural standards. US tariff reductions on Indian generic pharmaceuticals, gems, diamonds, aircraft parts, and certain automotive components are flagged as contingent on completion of the full Interim Agreement.

The Commonwealth of Pennsylvania, via Governor Josh Shapiro's office and the Department of Community & Economic Development, assembled a $100 million public incentive package — up to $50 million via the PA Edge Tax Credit Program, a $25 million PA SITES (Strategic Investments to Enhance Sites) grant, a $25 million Pennsylvania First grant, and up to $5 million via the Redevelopment Assistance Capital Program (RACP) for workforce development — to secure a $3.5 billion private investment from Eli Lilly and Company, the company's first manufacturing facility in Pennsylvania. The 925,000-square-foot facility will be built at the Fogelsville Corporate Center in Upper Macungie Township, Lehigh County, to produce next-generation weight-loss medicines, creating at least 850 new jobs over five years. It is the largest life-sciences investment in Pennsylvania history.

Malaysia replaced its four-decade-old Promotion of Investments Act (PIA) 1986 manufacturing-incentive regime with the New Incentive Framework (NIF), effective 1 March 2026. Applications under PIA 1986 closed at 15:00 MYT on 28 February 2026; post-March applications are evaluated under the outcome-based National Investment Aspirations (NIA) Scorecard across six economic-outcome pillars. Companies choose between two mutually exclusive incentive options — a special corporate tax rate or an investment tax allowance — aligned with the Global Minimum Tax environment. A services-sector phase is scheduled for Q2 2026.

Brazil's Câmara de Comércio Exterior (Gecex) approved Resolução nº 848, de 29 de janeiro de 2026, amending Annexes IV (supply-shortage tariff reductions), V (Letec exceptions list) and VI (LEBIT/BK — IT/telecom and capital-goods exceptions list) of the base tariff-nomenclature resolution (Gecex nº 272/2021). The measure grants a new 0% duty-free tariff-rate quota of 2,500 tonnes/year for poly(oxyethylene) methallyl ether (HPEG, NCM 3907.29.92) through 26 November 2026; adds 0% duty treatment for an esketamine hydrochloride nasal-spray medicine (NCM 3004.90.39) and several pharmaceutical active ingredients including amprenavir and efavirenz (NCM 3004.90.78); and adds cellular base-station antennas (NCM 8517.71.20, 25,000-unit quota through 19 August 2026), diesel-electric locomotives (NCM 8602.10.00, through 25 February 2027) and panoramic maxillary X-ray equipment (NCM 9022.13.11, at a 12.6% rate) to the LEBIT/BK exceptions list. Most changes take effect 1 February 2026 (some 2 February 2026); Article 7 directs SECEX to publish complementary quota-allocation criteria.

The European Investment Bank signed a EUR 400 million, seven-year loan agreement with Swedish hygiene and health group Essity on 29 January 2026 (EIB project ref. 20210374, "Essity Health and Hygiene Products RDI") to finance research, development and innovation expenditure at Essity's R&D centres in Sweden, Germany and France over 2025-2028. The financing targets product and process development across Personal Care, Professional Hygiene and medical wound care, with emphasis on replacing fossil-based plastics with bio-based materials, cutting greenhouse-gas emissions and expanding digital manufacturing solutions; roughly 30% of the RDI spend is earmarked for feminine-care and incontinence-product research. Global Trade Alert separately logs the transaction as a "red"-flagged state-linked lending intervention (state act 96020 / intervention 151945).

India's DGFT issued Notification No. 56/2025-26 on 29 January 2026, amending the import policy under Chapter 29 of ITC (HS) 2022 to impose minimum import prices (MIPs) on three antibiotic Active Pharmaceutical Ingredients (APIs): Penicillin G-potassium (₹2,216/kg CIF), Amoxycillin trihydrate (₹2,733/kg CIF), and 6-Aminopenicillanic Acid/6-APA (₹3,405/kg CIF). Imports below these price floors are reclassified from "Free" to "Restricted" status, requiring a DGFT import authorisation before Customs clearance. The measure takes immediate effect and is valid for approximately ten months (until 30 November 2026), with an implied renewal pathway. It is explicitly aimed at preventing very-low-priced imports and supporting domestic manufacturers built under the PLI Bulk Drugs scheme, targeting China's dominant position in global antibiotic-fermentation supply.

The UK Department of Health and Social Care added Co-codamol (30mg/500mg, all formulations) to its list of medicines that cannot be parallel-exported from the UK or hoarded, effective 28 January 2026. DHSC had issued a medicine supply warning for co-codamol 30mg/500mg on 12 January 2026, projecting limited supply into at least early June 2026. The restriction is issued under regulation 43(2) of the Human Medicines Regulations 2012; breach constitutes a wholesale dealer licence violation enforceable by the MHRA with licence suspension.

On 27 January 2026 the European Union and India announced the conclusion of negotiations on a comprehensive Free Trade Agreement at the EU-India summit hosted at Hyderabad House in New Delhi, attended by PM Narendra Modi, Commission President Ursula von der Leyen and Council President António Costa. The deal — described by both leaders as the "mother of all deals" — covers ~25% of world GDP and ~2 billion people. The EU eliminates duties on 91% of tariff lines (covering 99.3% of bilateral trade by value); India eliminates duties on 86% of lines (covering 96.6% by value). Headline cuts include Indian tariffs on EU wines (150% → 75% at entry into force, falling to 20%), olive oil (45% → 0% over five years) and processed agri-food (up to 50% eliminated); EU tariffs are reduced/eliminated on Indian textiles, leather/footwear, gems and jewelry, marine products, tea, coffee, spices and certain agricultural and steel products. The agreement still requires Council adoption, European Parliament consent and approval by India's Union Council of Ministers; entry into force is expected in early 2027. Companion instruments concluded at the same summit include an EU-India Security and Defence Partnership and a Mobility and Migration Agreement.

On 26 January 2026 Beijing's Dongcheng District (via the Zhongguancun Science Park Dongcheng Zone Management Committee and the district Science and Technology Commission) issued Notice 东城园文〔2026〕2号, "Several Measures of Beijing Dongcheng District on Promoting High-Quality Development of the Pharmaceutical and Health Industry," effective 25 February 2026. The 14-article package spans seven chapters covering traditional-Chinese-medicine industry development, product-innovation value realisation, digital medical services, innovative-medicine support, and talent services, with cash grants of up to RMB 20 million per project and up to RMB 10 million per year for a single market entity in the medical-device segment. A draft version was open for public comment from 18 December 2025 to 17 January 2026 before formal issuance.

The British Business Bank, the UK government's state-owned economic development bank, announced a GBP 50 million cornerstone commitment to Epidarex Capital's new life sciences fund on 20 January 2026. The fund, Epidarex Capital IV, LP, went on to announce a first close of USD 145 million on 27 January 2026, with the Bank joined by the Strathclyde Pension Fund, the Scottish National Investment Bank, and other family-office and corporate investors. This is the Bank's second cornerstone commitment to an Epidarex fund, following a GBP 50 million stake in Epidarex Capital III UK, LP in 2020.

China's Ministry of Finance, NDRC, Ministry of Industry and Information Technology, People's Bank of China and National Financial Regulatory Administration jointly issued Cai Jin [2026] No. 4 on 2026-01-19, establishing a central-fiscal loan interest-subsidy scheme for micro, small and medium-sized enterprises (MSMEs) operating in 14 designated industrial-chain and emerging-industry sectors. Eligible loans originated from 2026-01-01 receive a 1.5-percentage-point annual interest subsidy for up to two years, capped at RMB 50 million in principal per enterprise (maximum subsidy RMB 1.5 million per enterprise). The policy is tentatively set to run one year with a possible extension.

On 15 January 2026, Brazil's Gecex executive committee (Câmara de Comércio Exterior) published Resolução nº 845, amending Annex IX of the base tariff-nomenclature resolution (Gecex nº 272/2021) to temporarily raise import duties above the Mercosur Common External Tariff on eight NCM product lines. Affected products include sodium pyrophosphate and ammonium carbonate (17.5%), propylene glycol, expandable polystyrene and polymethyl methacrylate (20%), sorbitol (20%, with a 12.6% carve-out for a specific food/pharma-grade aqueous solution), and wood screws (25%). The increases took effect 19 January 2026 and expire 18 January 2027, a one-year window functioning as a safeguard-style protection for domestic chemical, plastics and fastener producers.

The UK Department of Health and Social Care added Aspirin (all strengths and forms) and Ifosfamide (1g/2g powder for solution for injection vials, a chemotherapy agent) to its list of medicines that cannot be parallel-exported from the UK or hoarded, effective 17 January 2026. Pharmacy trade press reported the addition followed manufacturing delays and raw- ingredient shortages that had left UK pharmacies short of aspirin stock. The restriction is issued under regulation 43(2) of the Human Medicines Regulations 2012; breach constitutes a wholesale dealer licence violation enforceable by the MHRA with licence suspension.

On 16 January 2026 the Saudi Council of Ministers, via Cabinet Decision No. 468/1447 (issued 30 December 2025 / 9 Rajab 1447H), published in the Umm Al-Qura Official Gazette four sets of implementing regulations governing the King Abdullah Economic City (KAEC), Ras Al-Khair, Jazan, and Cloud Computing & IT Special Economic Zones. The regulations entered into force on 16 April 2026 (90 days after gazette publication) and operationalise the SEZ framework first launched by ECZA in April 2023. Each zone has its own standalone framework but they share a common headline tax package: 5% corporate income tax for up to 20 years, zero VAT on intra-SEZ and SEZ-import flows, customs-duty suspension on qualifying imports, withholding-tax exemption on dividends and approved cross-border payments, and exemption from key provisions of the Saudi Companies Law, Commercial Register Law, and Trade Names Law. KAEC focuses on advanced manufacturing, automotive, consumer goods, ICT and pharmaceuticals; Ras Al-Khair targets shipbuilding, offshore rigs and MRO; Jazan covers food processing, metals conversion and logistics for Africa-bound trade; the Cloud Computing SEZ is a virtual zone (data centres can sit anywhere in KSA, headquarters must be in Riyadh) for cloud and AI-compute workloads. The package is the operational implementation layer for the 2024 Investment Law and a core Vision 2030 FDI-attraction instrument.

On 14 January 2026 President Trump issued a Presidential Proclamation under Section 232 of the Trade Expansion Act of 1962 titled "Adjusting Imports of Processed Critical Minerals and Their Derivative Products into the United States". Unlike the parallel 14 January 2026 semiconductor proclamation and the subsequent April 2026 pharmaceutical proclamation, the PCMDP proclamation does NOT immediately impose tariffs. Instead it directs the Secretary of Commerce and the U.S. Trade Representative to jointly negotiate bilateral and plurilateral supply agreements with trading partners, with an initial 180-day status report due 13 July 2026. The proclamation reserves residual authority to impose tariffs if negotiations fail or prove ineffective, and explicitly contemplates "price floors" on PCMDP imports as a negotiated instrument.